Steward Partners Investment Advisory LLC Has $7.43 Million Stake in Edwards Lifesciences Co. (NYSE:EW)

Steward Partners Investment Advisory LLC cut its position in Edwards Lifesciences Co. (NYSE:EW) by 4.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 100,297 shares of the medical research company’s stock after selling 4,810 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Edwards Lifesciences were worth $7,425,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. LGT Group Foundation raised its position in Edwards Lifesciences by 29.6% during the fourth quarter. LGT Group Foundation now owns 58,521 shares of the medical research company’s stock valued at $4,332,000 after purchasing an additional 13,370 shares in the last quarter. SBI Securities Co. Ltd. bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at $62,000. Jones Financial Companies Lllp increased its stake in shares of Edwards Lifesciences by 19.9% in the 4th quarter. Jones Financial Companies Lllp now owns 8,014 shares of the medical research company’s stock valued at $593,000 after purchasing an additional 1,329 shares during the last quarter. SRS Capital Advisors Inc. raised its holdings in shares of Edwards Lifesciences by 74.0% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,702 shares of the medical research company’s stock worth $126,000 after buying an additional 724 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its position in shares of Edwards Lifesciences by 16.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 5,789 shares of the medical research company’s stock worth $430,000 after buying an additional 797 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW opened at $72.89 on Thursday. The firm’s fifty day simple moving average is $72.45 and its two-hundred day simple moving average is $70.35. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $42.99 billion, a P/E ratio of 10.46, a price-to-earnings-growth ratio of 4.82 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analysts Set New Price Targets

EW has been the topic of a number of recent analyst reports. Canaccord Genuity Group lifted their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research report on Thursday, February 13th. Royal Bank of Canada reiterated an “outperform” rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Evercore ISI cut their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday, February 12th. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Finally, Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price objective for the company from $82.00 to $90.00 in a report on Monday, December 16th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $79.95.

Insider Activity

In other news, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the transaction, the chief financial officer now directly owns 30,561 shares in the company, valued at $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 37,739 shares of company stock worth $2,799,104 in the last quarter. 1.29% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.